Gland Pharma gets USFDA nod for Latanoprostene Bunod Ophthalmic Solution'

Gland Pharma received approval from the USFDA for its Abbreviated New Drug Application for Latanoprostene Bunod Ophthalmic Solution, 0.024%.

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VYZULTA Ophthalmic solution, 0.04%, of Bausch and Lomb, Inc.

This Product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity.

Gland Pharma closed at Rs. 1,399.15, down by 0.98%, with a volume of 9371 shares on the BSE.